Sunflower Pharmaceutical GroupLtd (002737) Stock Overview
Engages in the research and development, manufacturing, and marketing of Chinese patent medicines in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
002737 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Sunflower Pharmaceutical Group Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥15.72 |
| 52 Week High | CN¥25.50 |
| 52 Week Low | CN¥15.33 |
| Beta | 0.29 |
| 1 Month Change | -0.064% |
| 3 Month Change | -6.71% |
| 1 Year Change | -36.20% |
| 3 Year Change | -1.93% |
| 5 Year Change | -3.14% |
| Change since IPO | 19.54% |
Recent News & Updates
Recent updates
There Is A Reason Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Price Is Undemanding
Jan 04
We Believe That Sunflower Pharmaceutical GroupLtd's (SZSE:002737) Weak Earnings Are A Good Indicator Of Underlying Profitability
Nov 04A Look At The Intrinsic Value Of Sunflower Pharmaceutical Group Co.,Ltd (SZSE:002737)
Aug 26Lacklustre Performance Is Driving Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Low P/E
Jul 19Sunflower Pharmaceutical GroupLtd's (SZSE:002737) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 07Earnings Troubles May Signal Larger Issues for Sunflower Pharmaceutical GroupLtd (SZSE:002737) Shareholders
May 06Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Subdued P/E Might Signal An Opportunity
Apr 16We Ran A Stock Scan For Earnings Growth And Sunflower Pharmaceutical GroupLtd (SZSE:002737) Passed With Ease
Mar 04Shareholder Returns
| 002737 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 0% | 3.7% | 1.2% |
| 1Y | -36.2% | 23.2% | 23.9% |
Return vs Industry: 002737 underperformed the CN Pharmaceuticals industry which returned 23.2% over the past year.
Return vs Market: 002737 underperformed the CN Market which returned 23.9% over the past year.
Price Volatility
| 002737 volatility | |
|---|---|
| 002737 Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 9.8% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 002737 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002737's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 5,727 | Yi Guan | www.kuihuayaoye.com |
Sunflower Pharmaceutical Group Co.,Ltd engages in the research and development, manufacturing, and marketing of Chinese patent medicines in China and internationally. The company produces chemical and biological medicines, and health care products. It also provides products covering various therapeutic areas, including pediatrics, gynecology, digestive system, respiratory and cold, rheumatic bone disease, and cardiovascular and cerebrovascular; supplements; and antibiotics and children’s medicinal products.
Sunflower Pharmaceutical Group Co.,Ltd Fundamentals Summary
| 002737 fundamental statistics | |
|---|---|
| Market cap | CN¥9.18b |
| Earnings (TTM) | CN¥293.97m |
| Revenue (TTM) | CN¥2.52b |
Is 002737 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002737 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.52b |
| Cost of Revenue | CN¥1.66b |
| Gross Profit | CN¥866.49m |
| Other Expenses | CN¥572.52m |
| Earnings | CN¥293.97m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 28, 2025
| Earnings per share (EPS) | 0.50 |
| Gross Margin | 34.35% |
| Net Profit Margin | 11.65% |
| Debt/Equity Ratio | 0% |
How did 002737 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/07 17:49 |
| End of Day Share Price | 2025/07/07 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sunflower Pharmaceutical Group Co.,Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wen Wen Shen | Avic Securities Co., Ltd |
| Bin Wu | China Merchants Securities Co. Ltd. |